Manufacturer: 

Contents:

Oral Contraceptives

Prevention of pregnancy.

Beginning on day 1 of cycle, 1 tab daily for 21 days.

Should be taken with food.

Diabetes w/ vascular changes; DVT, thromboembolism (current or history), cerebrovascular or coronary artery disease, thrombogenic valvulopathies, thrombogenic rhythm disorders, uncontrolled hypertension, breast carcinoma or other oestrogen-dependent neoplasia, hepatic adenomas or carcinomas, or active liver disease, as long as liver function has not returned to normal.

Thromboembolic disorders, smoking, hypertension, hyperlipidemia, obesity & diabetes. Carcinoma of the breast & cervix; hepatic neoplasia; gallbladder disease; bleeding irregularities; pregnancy & lactation. Immediate discontinuation of Minulet: Symptoms of migraine, acute disturbance of vision, hearing or speech. 1st symptoms of thrombophlebitis or thromboembolism. Jaundice, hepatitis or generalized pruritus; increased epileptic seizure; rise in BP; severe clinical depression; severe upper abdominal pain or liver enlargement, 4 wks prior to & for 2 wks after elective surgery. Increased risk of thrombosis during prolonged immobilisation.

Headache, asthenia, elevated BP, nausea, flatulence, vomiting; Edema, hypercholesterolemia, wt gain, depression, dizziness/vertigo, emotional lability, nervousness; acne; Breast pain, dysmenorrhea, metrorrhagia, amenorrhea, breast engorgement, breast enlargement, breast neoplasm, cervix disorder, leukorrhea, menorrhagia, vaginitis; changes in libido, abdominal pain.

Rifampin, barbiturates, hydantoins, primidone, phenylbutazone, griseofulvin, penicillin & tetracyclines. Requirements for oral antidiabetic agents & insulin may be altered as a result of an effect in glucose tolerance, indinavir, fluconazole, troleandomycin, cyclosporine, theophylline, corticosteroids, phenytoin, rifabutin, ritonavir, atorvastatin, dexamethasone, topiramate.

Not established